Study Finds Ozempic Does Not Slow Alzheimer's Disease Progression
By
danso
6mo ago· 1 min readenNews
46/100
Doughy
Bagelometer↗
Looks the part, but the middle's still raw. Chew with caution.
Score46TypenewsSentimentnegative
Summary
Novo Nordisk announced that its popular weight-loss drug Ozempic does not slow the progression of Alzheimer's disease, based on results from a two-year study. While the drug has shown benefits for weight reduction and early data suggested potential benefits for various conditions including brain disorders, the study found it ineffective for Alzheimer's. The news caused Novo Nordisk's shares to fall 6%.
Key quotes
· 4 pulledOzempic does not slow Alzheimer's progression, its manufacturer Novo Nordisk said following a two-year study.
The popular drug reduces body weight by on average around 15% in obese patients, and early data suggested it may also slow the progress of some brain conditions.
The question had always been how much those changes were consequences of reducing obesity, or a confounding effect: Patients who take Ozempic might be more health-conscious.
There has been a tempering of some of the more exciting claims — it also failed to slow neur
Novo Nordisk’s shares fell 6% on the news.
